Hoth Therapeutics Secures EU Authorization in Spain for HT-001 Phase 2a Trial; Interim Data Show Efficacy in EGFRi Skin Toxicities

What happened

Hoth Therapeutics announced regulatory clearance in Spain for its Phase 2a CLEER Trial of HT-001, a topical treatment for EGFR inhibitor-induced skin toxicities, and reported interim data demonstrating meaningful reductions in rash and pruritus without treatment disruptions. This milestone expands the trial's European footprint, enabling multi-country enrollment and potentially accelerating patient recruitment. The interim results, while qualitative, suggest a favorable safety profile and efficacy signal, supporting HT-001's potential as a first-in-class supportive care therapy. However, the company's financial position remains precarious: with only $7.85M cash and a nine-month burn of $9.78M as of Q3 2025, continued equity dilution is likely, and the data are not yet statistically robust. While the news is a positive catalyst that may improve sentiment, it does not resolve the core investment thesis risks of high dilution, binary trial outcomes, and limited runway.

Implication

The Spanish authorization and interim efficacy data incrementally improve HT-001's probability of success, supporting the bull case for a potential partnering deal and triggering a reassessment of the drug's value. However, the fundamental risks outlined in the DeepValue report—high share count growth (88% in 2025), cash runway under 12 months, and reliance on equity financing—are not alleviated by this news. Investors should watch for concrete enrollment numbers, additional interim data, and signs of non-dilutive capital. The stock's current price around $0.89 is above our attractive entry of $0.70, offering limited margin of safety. We recommend waiting for either a pullback closer to cash value or for HT-001 to produce statistically robust Phase 2 results before upgrading the rating.

Thesis delta

The positive interim data and European regulatory progress increase the probability of the bull scenario (from 20% to ~25-30%) by accelerating the path to a Phase 2 readout and potential partnering. However, the bear case dilution risk remains elevated given the cash burn; the thesis skew is now slightly more balanced but still favors a WAIT stance. The key shift is that HT-001 now has stronger proof-of-concept, reducing binary risk, but the capital structure concerns remain unchanged. We would upgrade to BUY only if the company secures non-dilutive funding or provides a clear path to cash flow breakeven.